Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Middleburgh, New York. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI),' which is the most favorable classification and indicates no further regulatory action is required. The inspection, previously intimated on May 17, 2025, has now been officially closed under 21 CFR 20.64(d)(3). This removes the regulatory overhang related to this facility's compliance status.
Positive for shareholders — the VAI classification is the best possible outcome and removes uncertainty around the Middleburgh facility. This typically supports stable operations and supply continuity for the company's API business serving the US market.